Locus Biosciences signs contract with CARB-X to advance $14 million precision medicine program to develop crPhage™ product targeting Klebsiella pneumoniae infections
- Tuesday, November 10, 2020, 7:13
- PR Newswire
- Add a comment
MORRISVILLE, N.C., Nov. 10, 2020 /PRNewswire/ –Locus Biosciences, a clinical-stage biopharmaceutical company, announced today that it has signed a contract with the global non-profit, Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to fund up to $12.5…
About the Author
admin has written 20655 stories on this site.